Breaking News Instant updates and real-time market news.

SCS

Steelcase

$19.11

-0.01 (-0.05%)

, NLTX

Neoleukin Therapeutics

$9.16

1.04 (12.81%)

18:29
12/17/19
12/17
18:29
12/17/19
18:29

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Steelcase (SCS) up 6.1%... Cintas (CTAS) up 2.7%. ALSO HIGHER: Columbia Sportswear (COLM) up 4.9% after entering S&P MidCap400... Uniti Group (UNIT) up 1.7% after entering S&P SmallCap600... Vince Holding (VNCE) up 0.6% after disclosing stock purchase by CEO... Merck (MRK) up 0.5% after FDA advisory committee votes to recommend Keytruda in NMIBC. DOWN AFTER EARNINGS: FedEx (FDX) down 6.5%. ALSO LOWER: Homology Medicines (FIXX) down 21.8% after disclosing initial data from pheNIX trial in PKU... Constellation Pharma (CNST) down 4.0% after offering stock for selling holders... Stars Group (TSG) down 2.5% after equity offering... Neoleukin Therapeutics (NLTX) down 2.4% after equity offering. Movers as of 18:15ET.

SCS

Steelcase

$19.11

-0.01 (-0.05%)

NLTX

Neoleukin Therapeutics

$9.16

1.04 (12.81%)

CTAS

Cintas

$261.14

0.34 (0.13%)

COLM

Columbia Sportswear

$94.19

-0.08 (-0.08%)

UNIT

Uniti Group

$7.57

0.14 (1.88%)

VNCE

Vince Holding

$19.30

2.58 (15.43%)

MRK

Merck

$89.00

-0.29 (-0.32%)

FDX

FedEx

$163.29

-0.81 (-0.49%)

FIXX

Homology Medicines

$21.75

-0.185 (-0.84%)

CNST

Constellation Pharmaceuticals

$47.12

1.99 (4.41%)

TSG

The Stars Group

$24.35

-0.6 (-2.40%)

  • 17

    Dec

  • 17

    Dec

  • 17

    Dec

  • 17

    Dec

  • 18

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

  • 18

    Dec

  • 18

    Dec

SCS Steelcase
$19.11

-0.01 (-0.05%)

10/07/19
RAJA
10/07/19
DOWNGRADE
RAJA
Raymond James steps away from three office furniture stocks
Raymond James analyst Budd Bugatch downgraded Herman Miller (MLHR) to Market Perform from Outperform, Knoll (KNL) to Outperform from Strong Buy, and Steelcase (SCS) to Market Perform from Strong Buy. While the analyst likes the business models and the long-term prospects for each company, he's taking a step back pending evidence that the potential some industry weakness in the next 9-12 months "either will not occur or be short-lived." The stocks may be able to be bought at lower prices if industry challenges cause some interim downshifts in revenues and earnings, Bugatch tells investors in a research note. He points out the Business and Institutional Furniture Manufacturers Association reported Wednesday that August incoming orders fell year-over-year by 2.7%. This was the second negative incoming order rate in the past three months, says Bugatch.
10/07/19
RAJA
10/07/19
DOWNGRADE
RAJA
Market Perform
Steelcase downgraded to Market Perform from Strong Buy at Raymond James
Raymond James analyst Beryl Bugatch double downgraded Steelcase to Market Perform from Strong Buy.
09/23/19
RAJA
09/23/19
NO CHANGE
Target $23
RAJA
Strong Buy
Steelcase price target raised to $23 from $21 at Raymond James
Raymond James analyst Budd Bugatch reaffirmed a Strong Buy rating for Steelcase and raised his price target to $23 from $21 following the company's second quarter results last week, saying results were above expectations. Bugatch tells investors in a research note that although the unsettled trade environment and stock market volatility have made many investors hesitant with concern that the end of the cycle may be near, he believes the industry is healthy and likely to remain so over the near term, and feels the strong demand environment, improved profitability of the EMEA segment, value optimization from the acquisitions additional partnerships and the introduction of new product will provide value to shareholders.
07/17/19
GHSC
07/17/19
DOWNGRADE
GHSC
Neutral
Steelcase downgraded to Neutral from Buy at Seaport Global
Seaport Global analyst Matt McCall downgraded Steelcase to Neutral from Buy saying the near-to-intermediate term nonresidential backdrop "appears far less supportive." Several key leading macro indicators have "softened noticeably" in the past year, and the backdrop looks similar to the 2014-2015 period that preceded a precipitous drop in stock prices for nonresidential names, McCall tells investors in a research note. Further, Steelcase has the most difficult comps in the group in the year ahead, adds the analyst.
NLTX Neoleukin Therapeutics
$9.16

1.04 (12.81%)

CTAS Cintas
$261.14

0.34 (0.13%)

11/21/19
JEFF
11/21/19
INITIATION
JEFF
Jefferies initiates Diversifed Services sector
Jefferies analyst Hamzah Mazari initiated select names across Diversified Services as part of his broader research note covering the Business Services industry. The analyst has a Buy rating on Cintas (CTAS) with a $308 price target, Bright Horizons (BFAM) with a $177 price target, BrightView (BV) with a $23 price target, and ServiceMaster (SERV) with a $43 price target. Mazari likes the M&A potential and employment decoupling at Cintas, revenue growth visibility and cross selling opportunity at Bright Horizons, low organic growth expectations and free cash flow potential at BrightView, and underappreciated international growth opportunity at ServiceMaster. The analyst also rates Aramark (ARMK), H&R Block (HRB), and Rollins (ROL) at Hold with respective $49, $28, and $38 price targets, noting that Aramark expectations are "too high" on activist involvement, H&R Block suffers from lack of catalysts, and Rollins' M&A potential appears to be "baked in" to its valuation.
11/13/19
BARD
11/13/19
NO CHANGE
Target $300
BARD
Outperform
Baird says Cintas short report 'weak and flawed,' recommends adding to positions
Baird analyst Andrew Wittmann said short-seller Spruce Point presented "a series of weak and flawed arguments which demonstrate poor understanding of the business model and the industry" in its report published this morning targeting Cintas. Of the five key topics of concern raised by Spruce Point, Wittmann said the only one he would not argue against is the stock's elevated valuation, as the shares recently have hit record valuations, but he adds that "You get what you pay for." On the allegations of fraudulent labor practices, Wittmann argues that Spruce Point is extrapolating a single inspection citation, which was an isolated incident, in a way that "succumbs to the anecdotal evidence fallacy." The analyst recommends adding to positions on any weakness and keeps an Outperform rating on Cintas with a $300 price target.
11/13/19
JPMS
11/13/19
NO CHANGE
JPMS
Overweight
Cintas management offers responses to short report's questions to JPMorgan
JPMorgan analyst Andrew Steinerman noted that a short report published this morning raised questions around fraudulent practices within Cintas' Fire Protection Services business. While he noted that Cintas management had not yet read the short report when he spoke with them, he said that company management indicated that there are no systemic issues of improper inspections or licensing practices and that they are confident in the policies and procedures in place. Responding to questions around fast growing accounts receivable recently, management said that the combination of SAP conversion and the large GK acquisition make it only natural that receivables are impacted. On questions of allegedly worsening cash collections, management responded that the low rates on commercial paper rates have been compelling and driving usage of short-term financing recently, Steinerman added. He has an Overweight rating on Cintas shares.
11/21/19
JEFF
11/21/19
INITIATION
Target $308
JEFF
Buy
Cintas initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Cintas with a Buy rating and $308 price target.
COLM Columbia Sportswear
$94.19

-0.08 (-0.08%)

11/25/19
DADA
11/25/19
DOWNGRADE
Target $96
DADA
Neutral
Columbia Sportswear downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst John Morris downgraded Columbia Sportswear to Neutral from Buy with a price target of $96, down from $129. The analyst cites the takeaways from his discussions with the company's management team on November 15th, which call for maintained Q4 revenue growth outllok of low-to-mid single digits due to the "challenging compares" as well as its ongoing "investment initiatives" into product innovation. Morris adds that his assumed and downgraded Neutral rating reflects the top compares against a strong Holiday quarter last year as well as the acknowledgement by the management that its carryover inventory is "slightly higher than planned".
11/25/19
DADA
11/25/19
DOWNGRADE
DADA
Neutral
Columbia Sportswear downgraded to Neutral from Buy at DA Davidson
DA Davidson downgraded Columbia Sportswear to Neutral from Buy.
10/07/19
WEDB
10/07/19
NO CHANGE
WEDB
Outperform
Columbia Sportswear added to Best Ideas List at Wedbush
Wedbush added Columbia Sportswear to its Best Ideas List, saying that it has exceeded expectations while consistently raising its outlook. Shares on the other hand have underperformed, trading at a 16% discount to historical levels possibly due to concerns over Chinese sourcing exposure and/or worries over slowing growth, both of which are unfounded in Wedbush's view. The firm has an Outperform rating on the stock.
08/07/19
STFL
08/07/19
NO CHANGE
STFL
G-III, Yeti have higher than average risk from List 4 tariffs, says Stifel
Stifel analyst Jim Duffy said the direct, unmitigated impact of a proposed 10% tariff on "List 4" goods imported from China is contained to a single digit percentage headwind to calendar 2020 earnings for most of the 18 Sports and Lifestyle Brands companies he covers, though he identified G-III Apparel (GIII), Yeti (YETI) and potentially Dick's Sporting Goods (DKS) as having higher than group average exposure to the risk. He awaits more tariff details before adjusting estimates, but said he is constructive on higher-end and globally diversified brands, such as Lululemon (LULU), Columbia Sportswear (COLM), Nike (NKE), Under Armour (UAA) and VF Corp. (VFC).
UNIT Uniti Group
$7.57

0.14 (1.88%)

03/19/19
SBSH
03/19/19
NO CHANGE
Target $8
SBSH
Sell
Uniti Group price target lowered to $8 from $11 at Citi
Citi analyst Michael Rollins lowered his price target for Uniti Group to $8 from $11 saying he remains concerned about the company's cash position and the continued demands on its balance sheet during 2019. He keeps a Sell rating on the shares.
03/25/19
RBCM
03/25/19
NO CHANGE
Target $9
RBCM
Sector Perform
RBC Capital adds Speculative Risk qualifier to Uniti Group
RBC Capital analyst Bora Lee keeps his Sector Perform rating on Uniti Group (UNIT) but adds a "Speculative Risk" qualifier and lowers the price target on the shares to $9 from $15. The analyst says the company's Q4 results last week were "solid", but the quarter was "overshadowed by the Windstream (WIN) situation", adding that the stock will likely "continue to experience volatility" from Windstream bankruptcy. Lee adds that installs were impacted by Hurricane Michael, even though the company "continues to expect the majority of its existing dark fiber and small cell construction projects to be completed" by the end of 2019.
07/03/19
MSCO
07/03/19
NO CHANGE
MSCO
Underweight
Next three months to be 'pivotal' for Uniti Group, says Morgan Stanley
Morgan Stanley analyst Simon Flannery previewed upcoming events in the bankruptcy process for Windstream (WIN), including a court hearing scheduled for July 26 and the assume/reject decision for the Uniti Group (UNIT) lease due on September 23, calling the next three month likely "pivotal" for Uniti shares. The analyst, who thinks that Windstream's financial position and declining performance require a significant lease cut that is not fully discounted in Uniti's share price, keeps an Underweight rating on the latter stock.
09/19/19
MSCO
09/19/19
NO CHANGE
MSCO
Morgan Stanley downgrades Communications Infrastructure view to In-Line
Morgan Stanley analyst Simon Flannery downgraded his Communications Infrastructure industry view to In-Line from Attractive, noting that the group is up about 100% since early 2016 and about 30% this year. The advance has driven more appropriate valuations for the group, but leaves a more balanced risk-reward, contends Flannery. As previously reported, he made three individual stock rating changes in conjunction with the industry rating change. Flannery upgraded QTS Realty Trust (QTS) to Overweight from Equal Weight, citing improved execution, exposure to stable enterprise revenue streams and the potential for its valuation to re-rate to peer averages. Flannery downgraded Digital Realty (DLR) and SBA Communications (SBAC), each to Equal Weight from Overweight, primarily based on valuations. He raised his price target on QTS shares to $56 from $48, raised his price target on Digital Realty to $122 from $118 and increased his SBA price target to $249 from $222. Others in the Communications Infrastructure group covered by Flannery include Crown Castle (CCI), CyrusOne (CONE), American Tower (AMT), Equinix (EQIX) and Uniti Group (UNIT).
VNCE Vince Holding
$19.30

2.58 (15.43%)

MRK Merck
$89.00

-0.29 (-0.32%)

12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.
12/12/19
STFL
12/12/19
NO CHANGE
Target $17
STFL
Buy
Stifel says TherapeuticsMD's Annovera 'insulated' against generic NuvaRing
After Amneal Pharmaceuticals (AMRX) announced this morning that it has received approval from the FDA to market EluRyng, the first generic version of Merck's (MRK) NuvaRing Stifel analyst Annabel Samimy said the new contraceptive vaginal ring entrant may pose a threat to NuvaRing, but she believes TherapeuticsMD's (TXMD) competitor in the class, Annovera, is "insulated" by key product profile distinctions. Samimy points to Annovera's differentiated progesterone and long-acting system to support her view that Annovera successful early launch should shielded from disruption. She maintains a Buy rating and $17 price target on TherapeuticsMD shares.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
FDX FedEx
$163.29

-0.81 (-0.49%)

12/12/19
MSCO
12/12/19
NO CHANGE
Target $78
MSCO
Underweight
Morgan Stanley cuts UPS, FedEx price targets on growing Amazon risk
Morgan Stanley analyst Ravi Shanker estimates Amazon (AMZN) is delivering 46% of U.S. packages bought on its platform through Amazon Logistics, its in-house logistics operation, and he believes "AMZNL" is already shipping at a run rate of over 2.5B packages annually in the U.S. as of August. He also continues to believe that a Third-Party Logistics offering is coming from the e-commerce giant, Shanker tells investors. Contrary to what he views as the general investor perception that Amazon is still in the very early stages of building out its logistics network, Shanker thinks "the already large and quick ramp of AMZNL represent a large opportunity-loss" and competitive risk for the parcel carrying leaders. He lowered his price target on UPS (UPS) to $78 from $85 and keeps an Underweight rating on the shares while trimming his FedEx (FDX) target to $111 from $120 and maintaining an Equal Weight rating on the stock.
12/12/19
UBSW
12/12/19
UPGRADE
Target $161
UBSW
Neutral
FedEx upgraded to Neutral from Sell at UBS
UBS analyst Thomas Wadewitz upgraded FedEx to Neutral from Sell with a price target of $161, up from $132. The analyst says his Sell thesis has essentially played out as fiscal 2020 earnings expectations have fallen sharply and the stock has also moved down. While he does not anticipate near term improvement in financial results from FedEx, he believes the shares now reflect the "bad news," limiting further downside.
12/12/19
12/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Home Depot (HD) upgraded to Outperform from Neutral at Credit Suisse with analyst Seth Sigman saying he believes Home Depot offers an attractive risk/reward after its recent pullback and Wednesday's guidance reset, with optionality on improving external and internal drivers in FY20. 2. General Electric (GE) upgraded to Buy from Neutral at UBS with analyst Markus Mittermaier saying the shares are at a "positive inflection point" into 2020 given GE's successful de-levering, "strong" estimated earnings growth in 2020 and 2021, and a tripling of free cash flow to $2.3B next year led by Aviation and Healthcare. 3. Starbucks (SBUX) upgraded to Overweight from Neutral at JPMorgan with analyst John Ivankoe saying he sensed a high degree of confidence that Starbucks' "growth at scale" agenda is working in the near and medium term, meeting if not exceeding set sales and margin objectives. 4. Kroger (KR) upgraded to Outperform from In Line at Evercore ISI. 5. EST FedEx (FDX) upgraded to Neutral from Sell at UBS with analyst Thomas Wadewitz saying his Sell thesis has essentially played out as fiscal 2020 earnings expectations have fallen sharply and the stock has also moved down. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/17/19
FBCO
12/17/19
NO CHANGE
Target $168
FBCO
Outperform
Amazon delivery decision shouldn't impact FedEx earnings, says Credit Suisse
Credit Suisse analyst Allison Landry says she does not expect (AMZN) decision to block third party sellers from using FedEx (FDX) Ground to deliver Prime packages to have a material impact on FedEx's earnings, at least in the short-run. She notes that ~70% of units from Amazon's third party business are Fulfilled by Amazon and the rest is seller-fulfilled. The analyst keeps an Outperform rating and $168 price target on FedEx shares.
FIXX Homology Medicines
$21.75

-0.185 (-0.84%)

11/01/19
11/01/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Digi International (DGII) initiated with an Outperform at Baird. 2. Wave Life Sciences (WVE) initiated with a Buy at Guggenheim. 3. PPG (PPG) resumed with an Equal Weight at Morgan Stanley. 4. Homology Medicines (FIXX) initiated with a Perform at Oppenheimer. 5. Sarepta (SRPT) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/19
OPCO
10/31/19
INITIATION
OPCO
Perform
Homology Medicines initiated with a Perform at Oppenheimer
Oppenheimer analyst Matthew Biegler initiated coverage of Homology Medicines with a Perform rating. The analyst is bullish on the long-term prospects of Homology's lead therapy, HMI-102, in the ongoing pheNIX trial, but believes investors "should have tempered expectations heading into initial data from pheNIX, which will likely include few patients and limited follow-up." Biegler said he is Perform-rated until the initial data from the pheNIX trial comes in.
10/31/19
OPCO
10/31/19
INITIATION
OPCO
Perform
Homology Medicines initiated with a Perform at Oppenheimer
Oppenheimer analyst Matthew Biegler initiated coverage of Homology Medicines with a Perform rating.
09/24/19
HCWC
09/24/19
NO CHANGE
Target $36
HCWC
Buy
Homology Medicines selloff on manuscript unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says the manuscript published in Molecular Therapy is an attempt at marginalizing Homology Medicines' second platform, its AAVHSC-based, non-nuclease, in vivo gene editing. The manuscript has no bearing on Homology's lead canonical gene therapy program, adds the analyst. The new manuscript, "while making profound claims, falls short in its objectives in many ways," contends Chattopadhyay. The analyst "strongly" disagrees with the observations of the Dudek et al. manuscript and consider the approximately 7% selloff yesterday in shares of Homology Medicines as potentially unwarranted. He remains a buyer on weakness heading into the end of 2019 canonical gene therapy data from HMI-102. Chattopadhyay keeps a Buy rating on Homology Medicines with a $36 price target.
CNST Constellation Pharmaceuticals
$47.12

1.99 (4.41%)

12/10/19
OPCO
12/10/19
NO CHANGE
Target $55
OPCO
Outperform
Constellation Pharmaceuticals price target raised to $55 at Oppenheimer
Oppenheimer analyst Silvan Tuerkcan raised his price target for Constellation Pharmaceuticals to $55 from $40 and maintained an Outperform rating after the company updated CPI-0610 data with efficacy stable in the key first-line population and excellent tolerability in all settings. Tuerkcan tells investors in a research note that overall, he continues to see monotherapy and add-on efficacy without Jakafi washout, which clearly demonstrate activity.
12/10/19
BARD
12/10/19
NO CHANGE
Target $65
BARD
Outperform
Constellation Pharmaceuticals price target raised to $65 from $35 at Baird
Baird analyst Michael Ulz raised his price target on Constellation Pharmaceutical to $65 from $35 to reflect his increased confidence in the potential of CPI-0610 following Phase 2 data presented at ASH. Overall, he believes the updated results confirm the drugs potential which meaningfully expands the market opportunity. Ulz reiterated his Outperform rating on Constellation Pharmaceutical shares.
11/07/19
JEFF
11/07/19
NO CHANGE
Target $40
JEFF
Buy
Constellation Pharmaceuticals price target raised to $40 from $17 at Jefferies
Jefferies analyst Maury Raycroft reiterated a Buy rating on Constellation Pharmaceuticals and raised his price target on the shares to $40 from $17, saying that Constellation's Phase 2 '0610 myelofibrosis data showed activity in 2L and 1L, which were "better than expected." At the annual ASH meeting, the company will have more 2L and 1L data, the analyst noted. Raycroft added that, provided data at ASH continue to be in-line with the abstract cut, Constellation should have a "productive" conversation with regulators on pivotal paths and next steps.
11/07/19
RBCM
11/07/19
NO CHANGE
Target $42
RBCM
Outperform
Constellation Pharmaceuticals price target raised to $42 from $20 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Constellation Pharmaceuticals to $42 and kept his Outperform rating after its ASH abstract release "demonstrating promising results in the first-line and Jakafi-refractory myelofibrosis populations." The analyst notes that the setup remains positive going into the conference, where the updated data will "further support" the potential for broader role of CPI-0610 in myelofibrosis.
TSG The Stars Group
$24.35

-0.6 (-2.40%)

09/23/19
JEFF
09/23/19
INITIATION
Target $18
JEFF
Hold
The Stars Group initiated with a Hold at Jefferies
Jefferies analyst David Katz started The Stars Group with a Hold rating and $18 price target. If successful in capturing share of the U.S. sports betting market over the next few years, the company's earnings will accelerate, its leverage will decline, and its equity will expand, Katz tells investors in a research note. However, he sees potential near-term volatility in the shares with the Street reliant on The Stars Group's ability to establish and meet expectations.
09/10/19
09/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wendy's (WEN) downgraded to Neutral from Buy at Guggenheim and BTIG. 2. The Stars Group (TSG) downgraded to Underweight from Equal Weight at Barclays. 3. Whiting Petroleum (WLL) and Jagged Peak Energy (JAG) downgraded to Neutral from Buy at BofA/Merrill. 4. Dollar General (DG) downgraded to Market Perform from Outperform at Bernstein with analyst Brandon Fletcher saying he believes its future story is well understood, and the upside is probably priced into the stock already. 5. Wells Fargo (WFC) downgraded to Neutral from Buy at UBS with analyst Saul Martinez citing his reduced estimates for earnings and lower net interest income along with the continued uncertainty and low visibility around the progress in the management's efficiency improvements. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/19
SUSQ
10/07/19
DOWNGRADE
SUSQ
Neutral
The Stars Group downgraded to Neutral from Positive at Susquehanna
The Stars Group is being acquired by Flutter Entertainment PLC for about $6B.
10/28/19
RBCM
10/28/19
INITIATION
Target $25.5
RBCM
Outperform
The Stars Group initiated with an Outperform at RBC Capital
RBC Capital analyst Julian Easthope initiated coverage of The Stars Group with an Outperform rating and $25.50 price target, calling the stock "a cheap way to play the potential acquisition by Flutter." The stock's roughly 10% discount to the bid suggests some regulatory risk, but he believes precedents set by competition authorities in the U.K. and Australia leave "a high chance" of the deal being completed, Easthope tells investors.

TODAY'S FREE FLY STORIES

HEXO

Hexo

$1.61

-0.17 (-9.55%)

15:00
01/17/20
01/17
15:00
01/17/20
15:00
Recommendations
Hexo analyst commentary  »

Hexo price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
01/17/20
01/17
15:00
01/17/20
15:00
General news
Treasury Action: the markets are little changed »

Treasury Action: the…

QGEN

Qiagen

$34.34

0.165 (0.48%)

14:51
01/17/20
01/17
14:51
01/17/20
14:51
Periodicals
Qiagen shares up 3% to $35.15 in afternoon trading »

CTFN's Diane Alter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

SWK

Stanley Black & Decker

$171.74

1.29 (0.76%)

14:49
01/17/20
01/17
14:49
01/17/20
14:49
Periodicals
Stanley Black & Decker in talks to buy Consolidated Aerospace, Reuters says »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AAPL

Apple

$316.97

1.64 (0.52%)

14:49
01/17/20
01/17
14:49
01/17/20
14:49
Periodicals
Apple may have to abandon lightning connector cable in Europe, BBC News says »

Members of the European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

SWK

Stanley Black & Decker

$171.72

1.27 (0.75%)

14:45
01/17/20
01/17
14:45
01/17/20
14:45
Periodicals
Stanley Black & Decker in talks to buy Consolidated Aerospace, Reuters says »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

LSCC

Lattice Semiconductor

$23.15

1.87 (8.79%)

, AAPL

Apple

$316.57

1.24 (0.39%)

14:39
01/17/20
01/17
14:39
01/17/20
14:39
Hot Stocks
Lattice Semiconductor rises as link to Apple acquisition highlighted »

Following a report from…

LSCC

Lattice Semiconductor

$23.15

1.87 (8.79%)

AAPL

Apple

$316.57

1.24 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

DB

Deutsche Bank

$8.43

-0.115 (-1.35%)

14:32
01/17/20
01/17
14:32
01/17/20
14:32
Periodicals
Deutsche Bank slashes investment bank bonuses by roughly 30%, Bloomberg says »

Deutsche Bank is lowering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

14:30
01/17/20
01/17
14:30
01/17/20
14:30
Options
MIAX SPIKES options volume over 100K contracts is new record »

MIAX SPIKES options…

INSG

Inseego

$9.23

0.76 (8.97%)

14:25
01/17/20
01/17
14:25
01/17/20
14:25
Options
Inseego call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSTG

NanoString

$30.44

-0.41 (-1.33%)

14:23
01/17/20
01/17
14:23
01/17/20
14:23
Hot Stocks
Pura Vida reports 5.37% passive stake in NanoString »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
01/17/20
01/17
14:17
01/17/20
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
01/17/20
01/17
14:16
01/17/20
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$70.39

-4.05 (-5.44%)

14:06
01/17/20
01/17
14:06
01/17/20
14:06
Hot Stocks
Lawmakers urge FTC to investigate Envestnet over sale of financial data »

Several U.S. lawmakers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SNCA

Seneca Biopharma

$3.80

2.55 (204.00%)

14:06
01/17/20
01/17
14:06
01/17/20
14:06
Syndicate
Seneca Biopharma announces exercise of warrants for $7.55M gross proceeds »

Seneca Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$7.41

0.19 (2.63%)

14:05
01/17/20
01/17
14:05
01/17/20
14:05
Options
DHT Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
01/17/20
01/17
14:05
01/17/20
14:05
General news
Action Economics Survey results: »

Action Economics Survey…

BGNE

BeiGene

$169.60

1.72 (1.02%)

14:03
01/17/20
01/17
14:03
01/17/20
14:03
Upgrade
BeiGene rating change  »

BeiGene upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNE

Sony

$72.46

-0.09 (-0.12%)

, CMCSA

Comcast

$47.43

0.57 (1.22%)

13:57
01/17/20
01/17
13:57
01/17/20
13:57
On The Fly
Box Office Battle: 'Bad Boys for Life' opens strong »

Welcome to "Box Office…

SNE

Sony

$72.46

-0.09 (-0.12%)

CMCSA

Comcast

$47.43

0.57 (1.22%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$38.33

0.3 (0.79%)

DIS

Disney

$144.67

-0.43 (-0.30%)

LGF.A

Lionsgate

$10.94

-0.34 (-3.01%)

LGF.B

Lionsgate

$10.30

-0.325 (-3.06%)

VIAC

ViacomCBS

$39.64

-0.41 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

BA

Boeing

$325.18

-6.82 (-2.05%)

13:46
01/17/20
01/17
13:46
01/17/20
13:46
Periodicals
Boeing tells CNBC 'making necessary updates' to MAX after report of new issue »

After ABC's David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BA

Boeing

$326.24

-5.76 (-1.73%)

13:43
01/17/20
01/17
13:43
01/17/20
13:43
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing down 2% to $325.88…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

VB

Vanguard Small-Cap Index Fund

$169.72

-0.13 (-0.08%)

, IVV

iShares Core S&P 500

$333.10

0.72 (0.22%)

13:43
01/17/20
01/17
13:43
01/17/20
13:43
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week creations…

VB

Vanguard Small-Cap Index Fund

$169.72

-0.13 (-0.08%)

IVV

iShares Core S&P 500

$333.10

0.72 (0.22%)

TLT

iShares 20+ Year Treasury Bond Fund

$138.05

-1.15 (-0.83%)

ESGU

iShares ESG MSCI U.S.A. ETF

$73.74

0.27 (0.37%)

VCSH

Vanguard Short-Term Corporate Bond Index Fund

$81.21

0.025 (0.03%)

SPY

SPDR S&P 500 ETF Trust

$331.63

0.73 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$326.27

-5.73 (-1.73%)

13:42
01/17/20
01/17
13:42
01/17/20
13:42
Periodicals
ABC learns of another software issue with Boeing 737 Max »

ABC's David Kerley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

JNJ

Johnson & Johnson

$148.97

0.72 (0.49%)

13:39
01/17/20
01/17
13:39
01/17/20
13:39
Periodicals
Judge slashes J&J verdict down to $6.8M from $8B in Risperdal suit, Law.com says »

Philadelphia Court of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

JNJ

Johnson & Johnson

$149.03

0.78 (0.53%)

13:17
01/17/20
01/17
13:17
01/17/20
13:17
Periodicals
Judge cuts J&J punishment in Risperdal case to $6.8M from $8B, Bloomberg reports »

On October 8, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.